Suspension from Quotation
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Immutep Limited has requested an immediate suspension of its securities from quotation pending an announcement regarding the outcome of a futility analysis for a Phase III trial. The company aims to prevent trading in an uninformed market while it prepares to disclose the trial results.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Immutep
- Trading Halt
- Half Yearly Report and Accounts
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
- Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
- Immutep Quarterly Activities Report Q2 FY26
Later from Immutep
- Reinstatement to Quotation
- TACTI-004 to be discontinued following futility analysis
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
- Update on Phase I Study of IMP761 for Autoimmune Diseases
- Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep